30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook

      review-article
      ,
      Journal of Neuroinflammation
      BioMed Central
      Autoimmune cerebellar ataxia, Cerebellitis, Paraneoplastic cerebellar degeneration, Autoantibodies, Purkinje cells, Metabotropic glutamate receptor 1 (mGluR1) antibodies, Homer-3 antibodies, Anti-Sj, Inositol 1,4,5-trisphosphate receptor 1 (ITPR1, I3PR) antibodies, Carbonic anhydrase-related protein VIII (CARP VIII) antibodies, Protein kinase gamma (PKCγ) antibodies, Anti-Ca, Rho GTPase activating protein 26 (ARHGAP26, GRAF) antibodies, Glutamate receptor delta2 (GluRδ2) antibodies, Anti-Yo, Cerebellar degeneration-related protein 2 (CDR2) antibodies, Cerebellar degeneration-related protein 2-like (CDR2L) antibodies, Purkinje cell antibody 2 (PCA-2), Anti-Tr, Delta notch-like epidermal growth factor-related receptor (DNER) antibodies, Anti-Nb, Anti-AP3B2, Neuronal adaptin-like protein (beta-NAP) antibodies, Voltage-gated calcium channel (VGCC) antibodies

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Serological testing for anti-neural autoantibodies is important in patients presenting with idiopathic cerebellar ataxia, since these autoantibodies may indicate cancer, determine treatment and predict prognosis. While some of them target nuclear antigens present in all or most CNS neurons (e.g. anti-Hu, anti-Ri), others more specifically target antigens present in the cytoplasm or plasma membrane of Purkinje cells (PC). In this series of articles, we provide a detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa head antibodies’ due to their characteristic somatodendritic binding pattern when tested by immunohistochemistry). To assist immunologists and neurologists in diagnosing these disorders, typical high-resolution immunohistochemical images of all 12 reactivities are presented, diagnostic pitfalls discussed and all currently available assays reviewed. Of note, most of these antibodies target antigens involved in the mGluR1/calcium pathway essential for PC function and survival. Many of the antigens also play a role in spinocerebellar ataxia. Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.

          Related collections

          Most cited references133

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

          Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). Results Seropositive patients were found to be predominantly female (p 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. Conclusion This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

            Antibodies to aquaporin-4 (also known as AQP4-Ab or NMO-IgG) are sensitive and highly specific serum markers of autoimmune neuromyelitis optica (NMO). Second-generation recombinant diagnostic assays can detect AQP4-Ab in >or=80% of patients with NMO, and a role for AQP4-Ab in the pathophysiology of this condition was corroborated by a series of in vitro studies that demonstrated disruption of the blood-brain barrier, impairment of glutamate homeostasis and induction of necrotic cell death by AQP4-Ab-positive serum. Additional evidence for such a role has emerged from clinical observations, including the demonstration of a correlation between serum levels of AQP4-Ab and disease activity. The finding of NMO-like CNS lesions and clinical disease following passive transfer of AQP4-Ab-positive serum in several independent animal studies provided definitive proof for a pathogenic role of AQP4-Ab in vivo. Together, these findings provide a strong rationale for the use of therapies targeted against B cells or antibodies in the treatment of NMO. In this Review, we summarize the latest evidence in support of a direct involvement of AQP4-Ab in the immunopathogenesis of NMO, and critically appraise the diagnostic tests currently available for the detection of this serum reactivity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

              paraneoplastic neurological syndromes (PNS) almost invariably predate detection of the malignancy. Screening for tumours is important in PNS as the tumour directly affects prognosis and treatment and should be performed as soon as possible. an overview of the screening of tumours related to classical PNS is given. Small cell lung cancer, thymoma, breast cancer, ovarian carcinoma and teratoma and testicular tumours are described in relation to paraneoplastic limbic encephalitis, subacute sensory neuronopathy, subacute autonomic neuropathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome (LEMS), myasthenia gravis and paraneoplastic peripheral nerve hyperexcitability. many studies with class IV evidence were available; one study reached level III evidence. No evidence-based recommendations grade A-C were possible, but good practice points were agreed by consensus. the nature of antibody, and to a lesser extent the clinical syndrome, determines the risk and type of an underlying malignancy. For screening of the thoracic region, a CT-thorax is recommended, which if negative is followed by fluorodeoxyglucose-positron emission tomography (FDG-PET). Breast cancer is screened for by mammography, followed by MRI. For the pelvic region, ultrasound (US) is the investigation of first choice followed by CT. Dermatomyositis patients should have CT-thorax/abdomen, US of the pelvic region and mammography in women, US of testes in men under 50 years and colonoscopy in men and women over 50. If primary screening is negative, repeat screening after 3-6 months and screen every 6 months up till 4 years. In LEMS, screening for 2 years is sufficient. In syndromes where only a subgroup of patients have a malignancy, tumour markers have additional value to predict a probable malignancy.
                Bookmark

                Author and article information

                Contributors
                +49-6221-56-4747 , sven.jarius@med.uni-heidelberg.de
                brigitte.wildemann@med.uni-heidelberg.de
                Journal
                J Neuroinflammation
                J Neuroinflammation
                Journal of Neuroinflammation
                BioMed Central (London )
                1742-2094
                17 September 2015
                17 September 2015
                2015
                : 12
                : 168
                Affiliations
                Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, D-69120 Heidelberg, Germany
                Article
                358
                10.1186/s12974-015-0358-9
                4573944
                26377319
                b091a135-83e5-4673-8235-0666e1d39be6
                © Jarius and Wildemann. 2015

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 15 May 2015
                : 2 July 2015
                Categories
                Review
                Custom metadata
                © The Author(s) 2015

                Neurosciences
                autoimmune cerebellar ataxia,cerebellitis,paraneoplastic cerebellar degeneration,autoantibodies,purkinje cells,metabotropic glutamate receptor 1 (mglur1) antibodies,homer-3 antibodies,anti-sj,inositol 1,4,5-trisphosphate receptor 1 (itpr1, i3pr) antibodies,carbonic anhydrase-related protein viii (carp viii) antibodies,protein kinase gamma (pkcγ) antibodies,anti-ca,rho gtpase activating protein 26 (arhgap26, graf) antibodies,glutamate receptor delta2 (glurδ2) antibodies,anti-yo,cerebellar degeneration-related protein 2 (cdr2) antibodies,cerebellar degeneration-related protein 2-like (cdr2l) antibodies,purkinje cell antibody 2 (pca-2),anti-tr,delta notch-like epidermal growth factor-related receptor (dner) antibodies,anti-nb,anti-ap3b2,neuronal adaptin-like protein (beta-nap) antibodies,voltage-gated calcium channel (vgcc) antibodies

                Comments

                Comment on this article